WuXi Biologics Financials

Market Capitalization HK$128.18 Billion as of Jan. 1, 2026

Valuations Metrics as of Jan. 3, 2026

Trailing PE	29.43
Forward PE	21.24
Price to Sales TTM	HK$6.60
Price to Book MRQ	HK$2.61
Enterprise to Revenue	6.21
Enterprise to EBITDA	18.31

Financial Reports as of Jun. 30, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-06-30
Profit Margin	20.92%
Operating Margin	27.37%
Return on Assets TTM	5.89%
Return on Equity TTM	10.51%

Income Statement

Revenue TTM	HK$22,335,958,294
Revenue per Share TTM	HK$4.96
Quarterly Revenue Growth	16.10%
Gross Profit TTM	HK$9,526,877,651
EBITDA	HK$7,341,734,606
Net Income to Common TTM	HK$4,673,676,305
Diluted EPS TTM	HK$1.09
Quarterly Earnings Growth YoY	56.00%

Balance Sheet

Total Cash MRQ	HK$13,966,255,240
Total Cash per Share MRQ	HK$3.08
Total Debt MRQ	HK$
Total Debt to Equity MRQ	10.41
Current Ratio MRQ	2.88
Book Value per Share MRQ	HK$12.29

Cash Flow

Operating Cash Flow TTM	HK$6,372,871,474
Levered Free Cash Flow TTM	HK$9,638,287

2269 Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding	4,068,902,309
Float Shares	3,538,032,625
Avg 10 Volume	20,721,915
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	13.64%
% Held by Institutions	33.52%

Stock Price Summary

Beta	0.50
Fifty Two Week Low	HK$15.62
Fifty Two Week High	HK$42.60
Fifty Two Week Change	48.99%
Day 50 MA	HK$33.28
Day 200 MA	HK$30.17

Dividends and Splits

Forward Annual Dividend Rate	HK$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	HK$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2020-11-16